Medtronic plans to acquire SPR Therapeutics, adding its FDA-cleared SPRINT nerve stimulation system for non-opioid chronic pain management. This expands Medtronic's neuromodulation portfolio and strengthens its U.S. pain market position. The stock is down 18.2% year-to-date but up 3.2% over the past week, with analysts suggesting it may be undervalued. Additional investments in cardiac digital health and a European software hub in Ireland signal growth initiatives.